PANG Pangaea Oncology, S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnostic platforms validation and pre-clinical services. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Zaragoza, Spain.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Pangaea Oncology (BME: PANG)
›
Pangaea Oncology (BME: PANG) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 199 employees.
The shares were at 1.470 EUR on 18 November 2026, down 13.5% over 52 weeks. Its 52-week range is 1.430 EUR to 1.750 EUR: the price is 16.0% below the high and 2.8% above the low.
Its market capitalisation is 52.84M EUR.
Pangaea Oncology reports return on equity of -16.9%, an operating margin of -27.9% and revenue up 6.6% year over year.
Its debt exceeds its cash by 2.48M EUR, a debt-to-equity ratio of 0.27. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.